PMID- 38171833
OWN - NLM
STAT- MEDLINE
DCOM- 20240105
LR  - 20240105
IS  - 0015-5691 (Print)
IS  - 0015-5691 (Linking)
VI  - 159
IP  - 1
DP  - 2024
TI  - [Development of early prediction and discriminating techniques for Lewy body 
      diseases].
PG  - 2-5
LID - 10.1254/fpj.23065 [doi]
AB  - The advent of a super-aged society poses urgent challenges in overcoming 
      age-related neurological disorders and extending a healthy lifespan. 
      Neurodegenerative diseases such as Alzheimer's disease, dementia with Lewy 
      bodies, and Parkinson's disease are characterized by the accumulation of 
      pathogenic proteins in the brain, leading to the formation of intracellular 
      aggregates known as pathological hallmarks. In the early stages of protein 
      accumulation, before the onset of clinical symptoms such as cognitive impairment 
      or motor dysfunction, brain inflammation begins to occur. Subsequently, neuronal 
      death progresses, and clinical symptoms manifest as dementia or Parkinson's 
      disease. Therefore, there is a need for early prediction of neurodegeneration and 
      the development of disease-modifying drugs for pre-symptomatic prevention. To 
      address this issue, we have focused on enhancing the degradation of amyloid-beta 
      protein by targeting Ca(2+)/calmodulin-dependent kinase II (CaMKII)/proteasome 
      system and on suppressing the propagation and uptake mechanisms of alpha-synuclein by 
      targeting fatty acid-binding proteins (FABPs) coupled with the long isoform of 
      dopamine D2 (D(2L)) receptor. Additionally, our analysis of FABP knockout mice 
      has revealed an increased expression of FABPs in the neurodegenerative process, 
      suggesting their involvement in mitochondrial dysfunction and neuronal death. 
      Based on these findings, this article highlights the physiological significance 
      of FABP family proteins in neurodegeneration and discusses the analysis of plasma 
      biomarkers for predicting neurodegenerative disorders and the discriminatory 
      methods for distinguishing between Alzheimer's disease, dementia with Lewy 
      bodies, and Parkinson's disease. Furthermore, we explore the potential of 
      ultra-early prediction of neurodegenerative disorders.
FAU - Kawahata, Ichiro
AU  - Kawahata I
AD  - Department of CNS Drug Innovation, Graduate School of Pharmaceutical Sciences, 
      Tohoku University.
FAU - Takeda, Atsushi
AU  - Takeda A
AD  - Department of CNS Drug Innovation, Graduate School of Pharmaceutical Sciences, 
      Tohoku University.
FAU - Fukunaga, Kohji
AU  - Fukunaga K
AD  - Department of CNS Drug Innovation, Graduate School of Pharmaceutical Sciences, 
      Tohoku University.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Yakurigaku Zasshi
JT  - Nihon yakurigaku zasshi. Folia pharmacologica Japonica
JID - 0420550
RN  - 0 (alpha-Synuclein)
SB  - IM
MH  - Animals
MH  - Mice
MH  - *Lewy Body Disease/diagnosis/pathology
MH  - *Parkinson Disease/diagnosis
MH  - *Alzheimer Disease/metabolism
MH  - Lewy Bodies/metabolism/pathology
MH  - alpha-Synuclein
MH  - *Neurodegenerative Diseases
EDAT- 2024/01/04 11:43
MHDA- 2024/01/05 06:43
CRDT- 2024/01/03 21:25
PHST- 2024/01/05 06:43 [medline]
PHST- 2024/01/04 11:43 [pubmed]
PHST- 2024/01/03 21:25 [entrez]
AID - 10.1254/fpj.23065 [doi]
PST - ppublish
SO  - Nihon Yakurigaku Zasshi. 2024;159(1):2-5. doi: 10.1254/fpj.23065.